Author: Aadarsh Patel | EQMint
Sudarshan Pharma Industries Limited has informed the BSE that its proposed acquisition of a stake in US-based Med Therapy Biotechnology Inc. is still under due diligence and has not yet received final approval from the target company’s board.
The company made the disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, providing an update on the proposal first communicated to the stock exchange on September 5, 2026.
Sudarshan Pharma Proposes 9.50% Stake
Under the proposed transaction, Sudarshan Pharma Industries plans to acquire 9.50% of the common stock of Med Therapy Biotechnology Inc.
Separately, Sudarshan Pharma’s Chairman and Managing Director Hemal Mehta and Joint Managing Director Sachin Mehta have each proposed to acquire a 1.50% stake in Med Therapy in their individual capacities.
If completed as proposed, the combined stake involving the company and its two promoters would amount to 12.50%.
However, the proposed transactions have not yet been completed.
Deal Remains Under Due Diligence
Sudarshan Pharma said the proposals are currently undergoing due diligence, while confirmation from the Board of Directors of Med Therapy Biotechnology is still awaited.
A formal board resolution from the US-based company is also pending.
The pharmaceutical company clarified that its earlier communication regarding the transaction was an intimation of the proposal and that a further update will be provided once there is a material development.
Why the Med Therapy Deal Is Important
The proposed investment would give Sudarshan Pharma an entry into a US-based biotechnology company and could support the company’s broader plans to expand its presence in the international healthcare and pharmaceutical space.
However, the transaction remains at a preliminary stage. The completion of due diligence, approval by Med Therapy’s board and other applicable steps will be necessary before the proposed stake acquisition can be finalised.
For investors, the next key development will therefore be confirmation from Med Therapy’s board and any subsequent announcement from Sudarshan Pharma regarding completion of the transaction.
Sudarshan Pharma Industries: Key Details
- Company: Sudarshan Pharma Industries Limited
- BSE Scrip Code: 543828
- ISIN: INE00TVO1023
- Registered Office: Borivali (West), Mumbai
- Chairman & Managing Director: Hemal Mehta
- Proposed corporate stake: 9.50%
- Proposed stake by Hemal Mehta: 1.50%
- Proposed stake by Sachin Mehta: 1.50%
- Potential combined stake: 12.50%
What Happens Next?
Sudarshan Pharma’s proposed investment in Med Therapy Biotechnology is not yet a completed acquisition. The transaction remains subject to due diligence and confirmation by Med Therapy’s Board of Directors.
The company is expected to provide further information to the stock exchange once there is a definitive development regarding the proposal.
For more such information, visit EQMint
Join our WhatsApp channel for timely updates: Whatsapp
